Análisis de la acción Champions Oncology Inc (CSBR)CSBRChampions Oncology Inc

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is a technology-enabled research organization engaged in creating technology solutions to be utilized in drug discovery and development. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. Its pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development. The Company operates in one segment pertaining to oncology services. Its research platform is a proprietary bank of Patient Derived Xenograft (PDX) models. Its PDX models are deployed into advanced vivo and ex vivo pharmacology platforms, providing an insight into therapeutic programs. The PDX bank is characterized at the molecular, phenotypic and pharmacological levels, which provides a differentiated layer of data for its oncology dataset. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, CSBR is not a strong buy due to its recent performance and financial indicators. The current price is $4.80, which is close to its 52-week low of $4.59, indicating limited upside potential. The RSI is at 45.33, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 22.88, which is relatively high compared to its historical performance. The main risk is the negative net income trend, with a net income of -667,000 in Q4 2026, reflecting ongoing profitability challenges.

1 analysts cover CSBR: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 12.00.